Joel Schneider, Carbon Biosciences president and CEO

Car­bon Bio­sciences emerges with a new vi­ral vec­tor to shake up the cys­tic fi­bro­sis gene ther­a­py field

Car­bon Bio­sciences wants to dis­rupt the field of AAV gene ther­a­py by tap­ping in­to a fam­i­ly of thou­sands of virus­es to find ones that al­low for the “next gen­er­a­tion of vi­ral de­liv­ery ve­hi­cles,” as CEO Joel Schnei­der puts it.

The Mass­a­chu­setts biotech emerged Tues­day with $38 mil­lion in part­ner­ship with the Cys­tic Fi­bro­sis Foun­da­tion to take a bo­cavirus-based — part of the broad­er par­vovirus web — gene ther­a­py in­to the clin­ic for the lung dis­or­der.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.